Overview

Adjunctive, Low-dose tPA in Primary PCI for STEMI

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.

Phase:

Phase 3

Details

Lead Sponsor:

Population Health Research Institute

Collaborator:

Heart and Stroke Foundation of Canada

Treatments:

Plasminogen
Tissue Plasminogen Activator